PubRank

I B Runnebaum

Author PubWeight™ 33.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 1995 1.84
2 Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001 1.59
3 p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999 1.45
4 Laparoscopic lymphocele fenestration in gynaecological cancer patients after retroperitoneal lymph node dissection as a first-line treatment option. BJOG 2013 1.42
5 Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2007 1.37
6 p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 1998 1.13
7 CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 2003 1.09
8 Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000 1.04
9 Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 1999 1.03
10 Surgical management of multiple bilateral fibroadenoma of the breast: the Ribeiro technique modified by Rezai. Anticancer Res 2009 1.00
11 Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res 1998 0.97
12 A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 2012 0.95
13 Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001 0.94
14 p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 1999 0.94
15 Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int J Cancer 1998 0.93
16 Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000 0.91
17 Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005 0.88
18 Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines. Gynecol Oncol 1993 0.86
19 Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol 2011 0.86
20 Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol 2013 0.86
21 Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Anticancer Res 1997 0.85
22 Chicken ovalbumin upstream promoter--transcription factor (COUP-TF) expression in human endometrial cancer cell lines. Anticancer Res 1997 0.83
23 Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther 2001 0.83
24 Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 2014 0.82
25 Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res 1997 0.82
26 Treatment of endometriosis of uterosacral ligament and rectum through the vagina: description of a modified technique. Hum Reprod 2009 0.82
27 Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 1999 0.81
28 Venous coupler for free-flap anastomosis. Anticancer Res 2009 0.81
29 Combined staging at one stop using MR mammography: evaluation of an extended protocol to screen for distant metastasis in primary breast cancer - initial results and diagnostic accuracy in a prospective study. Rofo 2012 0.81
30 [Clinical value of computer-assisted analysis in MR mammography. A comparison between two systems and three observers with different levels of experience]. Rofo 2008 0.80
31 Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients. Cancer Epidemiol Biomarkers Prev 1995 0.80
32 Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients. Int J Mol Med 2000 0.80
33 Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors. Ann Oncol 2008 0.78
34 Potential of MR mammography to predict tumor grading of invasive breast cancer. Rofo 2011 0.77
35 Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL). Anticancer Res 1994 0.77
36 [Vulvodynia]. Hautarzt 2005 0.77
37 Sentinel lymph node biopsy in vulvar cancer: a pilot study. Eur J Gynaecol Oncol 2009 0.77
38 Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer. Anticancer Res 1998 0.75
39 Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Anticancer Res 1997 0.75
40 [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression]. Geburtshilfe Frauenheilkd 1995 0.75
41 Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. Oncol Rep 1998 0.75
42 Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J Cancer Res Clin Oncol 2000 0.75
43 [Choriocarcinoma]. Rofo 2006 0.75
44 Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines. Oncol Rep 2001 0.75
45 [Space-occupying tumor of the temporal region with facial nerve palsy, vestibular dysfunction and hearing loss]. HNO 2011 0.75